MONOCLONAL ANTIBODIES AND OTHER TARGETING AGENTS

单克隆抗体和其他靶向药物

• 批准号: 3616804
• 负责人: ALBERT F LOBUGLIO
• 金额: $ 5.89万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-03-31 至 1994-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3616804
• 关键词: monoclonal antibody

This clinical contract supports the design and conduct of Phase I/II clinical trials of monoclonal antibodies, immunoconjugates and other targeting agents alone or in combination with other investigational or standard therapy. This is a shared contract between the Division of Cancer Treatment, Biological Resources Branch, and the Cancer Therapy Evaluation Branch. These trials will focus on studies of mechanisms of anti-tumor response and immune modulation. Current areas of emphasis include the elucidation of complex interactions between the biological agent(s), the host effector cells and the tumor which may lead to tumor regression. Thus, ADCC, TIL activation, and the induced inflammatory response will be under scrutiny. In addition, detailed studies will be performed of pharmacokinetics and biodistribution, which are intended to lead to better application of monoclonal antibodies to deliver radionuclides, toxins and drugs to tumor cell targets. Of special interest will be the influence on these processes of specific modifications of monoclonal antibodies, such as changes in affinity, isotype, chimerization and substitution of F(ab')2 fragments.

该临床合同支持I/II期的设计和行为 单克隆抗体，免疫偶联物和其他的临床试验 单独或与其他研究或联合靶向剂 标准疗法。 这是划分之间的共同合同 癌症治疗，生物资源分支和癌症治疗 评估分支。 这些试验将集中于研究机制 抗肿瘤反应和免疫调节。 当前重点领域 包括阐明生物学之间的复杂相互作用 药物，宿主效应细胞和可能导致肿瘤的肿瘤 回归。 因此，ADCC，TIL激活和诱导的炎症 回应将受到审查。 此外，详细的研究将是 进行药代动力学和生物分布，旨在 导致更好地应用单克隆抗体来递送 放射性核素，毒素和药物对肿瘤细胞靶标。 特别 兴趣将是对这些特定过程的影响 单克隆抗体的修饰，例如亲和力的变化， f（ab'）2片段的同型，嵌合和取代。

项目成果

Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy.

对肿瘤抗原具有特异性的嵌合抗体：抗体治疗后对肿瘤的原位定位的证明。

• DOI: 10.3109/10520299809141109
• 发表时间: 1998
• 期刊: Biotechnic & histochemistry : official publication of the Biological Stain Commission
• 作者: Saleh,MN;Tilden,AB;Meredith,RF;LoBuglio,AF;Grizzle,WE
• 通讯作者: Grizzle,WE

Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.

模拟 GD2 抗原的人抗独特型抗体的生成。

• 发表时间: 1993
• 期刊: Journal of immunology (Baltimore, Md. : 1950)
• 作者: Saleh,MN;Stapleton,JD;Khazaeli,MB;LoBuglio,AF
• 通讯作者: LoBuglio,AF

Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.

鼠单克隆抗 GD2 抗体 14G2a 治疗转移性黑色素瘤的 I 期试验。

• 发表时间: 1992
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Saleh,MN;Khazaeli,MB;Wheeler,RH;Dropcho,E;Liu,T;Urist,M;Miller,DM;Lawson,S;Dixon,P;Russell,CH
• 通讯作者: Russell,CH

Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

嵌合抗 GD2 单克隆抗体 ch14.18 在恶性黑色素瘤患者中的 I 期试验。

• 发表时间: 1992
• 期刊: Human antibodies and hybridomas
• 作者: Saleh,MN;Khazaeli,MB;Wheeler,RH;Allen,L;Tilden,AB;Grizzle,W;Reisfeld,RA;Yu,AL;Gillies,SD;LoBuglio,AF
• 通讯作者: LoBuglio,AF